Brief: Sesen Bio -FDA Granted Request For Meeting To Discuss Remaining Items For Additional Phase 3 Trial Related To Potential BLA Resubmission For Vicineum

Carisma Therapeutics

20/05/2022 14:05

Sesen Bio Inc  SESN.O :
    * SESEN BIO -FDA GRANTED REQUEST FOR MEETING TO DISCUSS
REMAINING
ITEMS FOR ADDITIONAL PHASE 3 TRIAL RELATED TO POTENTIAL BLA
RESUBMISSION FOR VICINEUM
    * SESEN BIO - FDA HAS DESIGNATED MEETING AS TYPE B MEETING
WHICH
IS SCHEDULED FOR JULY 11, 2022
    * SESEN BIO - CO PREPARES FOR TYPE B MEETING,  EVALUATES
ADDITIONAL PHASE 3 CLINICAL TRIAL, WILL CONTINUE PROCESS TO
REVIEW STRATEGIC ALTERNATIVES

Source text for Eikon:  ID: 
Further company coverage:  SESN.O